Citicoline (CDP-choline): mechanisms of action and effects in ischemic brain injury.
Sandage BW Jr.
Interneuron Pharmaceuticals Inc.
Lexington, MA 02173.
Neurol Res 1995 Aug;17(4):281-4
CDP-choline is approved in
Europe and Japan for use in stroke, head trauma and other neurological
disorders. It is presently being evaluated in phase II/III stroke trials
in the United States. Exogenous administration of CDP-choline provides
both choline and cytidine which access the brain and serve as substrates
for the synthesis of phosphatidylcholine, a primary neuronal membrane
component; the choline also enhances brain acetylcholine synthesis.
Membrane repair and regeneration is necessary for recovery from stroke.
Furthermore, CDP-choline may alleviate free fatty acid-induced toxicity,
which accompanies ischemic insult. Data from many pre-clinical and
clinical trials support the hypothesis that citicoline may be a safe and
effective treatment for stroke.